Antibody-Drug Conjugates in Cancer Therapy: Innovations, Challenges, and Future Directions
Antibody-drug conjugates (ADCs) have emerged as a promising approach for cancer treatment, garnering significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules, they enhance the therapeutic index, selectively targeting cancer cells while minimizing systemic toxicity. However, several challenges remain: including the selection of appropriate target antigens, enhancing antibodies, … Read more
